PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

NCT00512980 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-12-03

No results posted yet for this study

Summary

A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma

Conditions

Interventions

DRUG

prednisone

DRUG

vinblastine

DRUG

doxorubicin

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Andreas Engert, Prof · University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2013-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00512980 on ClinicalTrials.gov